Abstract: A gearbox for a motor vehicle drivetrain is provided including a gearbox housing; and a differential inside of the gearbox housing configured for driving a first output shaft and a second output shaft about a center axis and for allowing the first output shaft and the second output shaft to rotate about the center axis at different speeds. The differential includes a first side gear on a first side of the differential configured for being drivingly connected to the first output shaft; a second side gear on a second side of the differential configured for being drivingly connected to the second output shaft; a differential housing radially surrounding the first and second side gears; and a first bearing rotatably supporting the differential housing with respect to the gearbox housing.

Abstract: A drive assembly for a motor vehicle drivetrain includes a differential configured for driving a first output shaft and a second output shaft about a center axis and for allowing the first output shaft and the second output shaft to rotate about the center axis at different speeds. The differential includes a first side gear on a first side of the differential configured for being drivingly connected to the first output shaft; a second side gear on a second side of the differential configured for being drivingly connected to the second output shaft; a differential housing enclosing the first and second side gears; support pins non-rotatably fixed to the differential housing; and spider gears rotatably mounted on the support pins and positioned between the first side gear and the second side gear. Each of the spider gears intermeshes with both the first side gear and the second side gear to transmit power from the support pins to the first side gear and the second side gear.

Abstract: A drive assembly with passive cooling and/or lubrication. The drive assembly includes a housing, an electric motor having a shaft that is rotatably drivable about an axis of rotation, and a gear assembly located in the housing. The gear assembly is rotatably drivable by the shaft, and includes a plurality of gears that are rotatable in a rotational drive direction. An oil removal opening is located on an inner wall of the housing aligned with the gears, with the oil removal opening being located between ?45 and +45 degrees from a horizontal plane that extends through the axis of rotation on a rotationally upward moving side of the gears in the rotational drive direction. The oil removal opening has an upper edge that is angled and faces counter to the rotational drive direction. An oil delivery channel extends from the oil removal opening to a feed port for the motor.

Abstract: A fluid system for a motor vehicle drivetrain is provided including a housing including drain hole, a first fluid chamber for receiving fluid, and a second fluid chamber for receiving fluid, the drain hole coupled to the first fluid chamber and the second fluid chamber for draining fluid from both the first fluid chamber and the second fluid chamber. The fluid system further includes a stopper configured to prevent fluid from draining from the first fluid chamber and the second fluid chamber out of the drain hole in a first orientation of the stopper and configured to allow fluid to drain from the first fluid chamber and the second fluid chamber out of the drain hole in a second orientation of the stopper. The stopper is configured to isolate the first fluid chamber from the second fluid chamber in the first orientation of the stopper.

Abstract: The present invention provides methods of determining a survival predictor score of a subject having mantle cell lymphoma (MCL). The present invention also provides methods of predicting the survival outcome of a subject having MCL and provides methods of selecting a treatment for a subject having MCL.

Abstract: In embodiments of the invention, the invention provides a method for distinguishing between lymphoma types based on gene expression measurements. In embodiments, the invention distinguishes between PMBCL and DLBCL based on gene expression signatures, and can further distinguish between DLBCL subtypes. In embodiments of the invention, the distinctions are used in methods of treatment.

Abstract: The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.

Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.

Abstract: Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.

Abstract: The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.

Abstract: In embodiments of the invention, the invention provides a method for distinguishing between lymphoma types based on gene expression measurements. In embodiments, the invention distinguishes between PMBCL and DLBCL based on gene expression signatures, and can further distinguish between DLBCL subtypes. In embodiments of the invention, the distinctions are used in methods of treatment.

Abstract: The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.

Abstract: The present invention provides methods of determining a survival predictor score of a subject having mantle cell lymphoma (MCL). The present invention also provides methods of predicting the survival outcome of a subject having MCL and provides methods of selecting a treatment for a subject having MCL.

Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.

Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.

Abstract: Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.

Abstract: The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.

Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.

Abstract: It has been surprisingly found that ZAP-70 expression, both at the protein and mRNA levels, is indicative of clinical subgroups of CLL/SLL patients. In particular, high ZAP-70 expression is indicative of Ig-unmutated CLL/SLL. Methods are provided for discriminating between clinical subgroups of CLL/SLL, by determining whether subjects overexpress ZAP-70 mRNA or protein.

Abstract: Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.